Radiopharm Theranostics (ASX: RAD) has announced that patient enrollment has commenced for the third cohort of its ongoing Phase 1 dose-escalation trial evaluating 177Lu-RAD204, a radiolabeled single-domain antibody targeting PD-L1 in advanced solid tumours. …
Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers
November 12, 2025 Australian Biotech
Latest Video
New Stories
-
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech -
Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - - Latest News -
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - - Latest News -
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - - Australian Biotech